Skip to main content

Current news

Tumor Profiler Center scientists describe strategy to target persister cancer cells

| News

Therapeutic resistance in cancer treatment can be divided into primary resistance (lack of response to initial therapy due to preexisting genetic mutations) and acquired resistance (relapse despite initial response, caused by intratumor heterogeneity and other factors). While genetic alterations are known to contribute to acquired resistance, recent evidence suggests the involvement of non-genetic adaptive mechanisms.


TPC scientists now show that metabolic reprogramming sensitizes resistant cancer cells to ROS-induction in combination with pathway inhibitors. Predictive biomarkers of metabolic sensitivity to ROS-inducing agents were identified in many cancer entities, highlighting the importance of this finding as a potential cancer treatment option.

Read more: ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.